Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment

Biomedicine and Pharmacotherapy

Volumn 63, Issue 10, 2009, Pages 723-733

  Derosa, Giuseppe ^a   D'Angelo, Angela ^a   Salvadeo, Sibilla A T ^a   Ferrari, Ilaria ^a   Fogari, Elena ^a   Gravina, Alessia ^a   Mereu, Roberto ^a   Palumbo, Ilaria ^a   Maffioli, Pamela ^a   Randazzo, Sabrina ^a   Cicero, Arrigo F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acarbose; Adipokines; Metalloproteinases; OGTT; Pioglitazone; Type 2 diabetes

Indexed keywords

ACARBOSE; ADENOSINE DIPHOSPHATE; ADIPOCYTOKINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GELATINASE A; GELATINASE B; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NITRATE; NITRITE; PIOGLITAZONE; RESISTIN; SULFONYLUREA;

ADIPOSE TISSUE; ADULT; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETIC PATIENT; DRUG DOSE TITRATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

ACARBOSE; ADIPOKINES; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLUCOSE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; THIAZOLIDINEDIONES;

EID: 71749093051     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.04.044     Document Type: Article

References (34)

1. Ahima R.S., and Osei S.Y. Adipokines in obesity. Front Horm Res 36 (2008) 182-197
2. Bulcão C., Ferreira S.R., Giuffrida F.M., and Ribeiro-Filho F.F. The new adipose tissue and adipocytokines. Curr Diabetes Rev 2 (2006) 19-28
3. Bełtowski J., Jamroz-Wiśniewska A., and Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 8 (2008) 7-46
4. Antuna-Puente B., Feve B., Fellahi S., and Bastard J.P. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metabol 34 (2008) 2-11
5. Kong A.P., Chan N.N., and Chan J.C. The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. Curr Diabetes Rev 2 (2006) 397-407
6. Garvin P., Nilsson L., Carstensen J., Jonasson L., and Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE 3 (2008) e1774
7. Cicero A.F., Derosa G., Manca M., Bove M., Borghi C., and Gaddi A.V. Vascular remodeling and prothrombotic markers in subjects affected by familial combined hyperlipidemia and/or metabolic syndrome in primary prevention for cardiovascular disease. Endothelium 14 (2007) 193-198
8. Derosa G., D'Angelo A., Tinelli C., Devangelio E., Consoli A., Miccoli R., et al. Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in diabetic and healthy subjects. Diabete Metab 33 (2007) 129-134
9. Miyazaki Y., and Defronzo R.A. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients. Diabetes Obes Metabol 10 (2008) 1204-1211
10. Ochiai H., Ooka H., Shida C., Ishikawa T., Inoue D., and Okazaki R. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. Endocrinol Jpn 55 (2008) 549-556
11. World Health Organization. Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity (June 1997), WHO, Geneva
12. American Diabetes Association. Nutrition recommendations and principles for people with diabetes mellitus (position statement). Diabetes Care 24 Suppl. 1 (2001) S44-S47
13. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 16 (1999) 716-730
14. Heding L.G. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8 (1972) 260-266
15. Klose S., and Borner K. Enzymatische bestimmung des gesamtcholesterins mit dem greiner selective analyzer (GSA II). J Clin Chem Clin Biochem 15 (1978) 121-130
16. Wahlefeld A.W. Triglycerides determination after enzymatic hydrolysis. In: Bermeyer H.U. (Ed). Methods of enzymatic analysis. 2nd English ed. (1974), Academic Press Inc, New York 18-31
17. Havel R.J., Edr H.A., and Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34 (1955) 1345-1353
18. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
19. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., and Tannenbaum S.R. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Anal Biochem 126 (1982) 131-138
20. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7 (2001) 941-946
21. Yannakoulia M., Yiannakouris N., Bluher S., Matalas A.L., Klimis-Zacas D., and Mantzoros C.S. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88 (2003) 1730-1736
22. Fujimoto N., Mouri N., Iwata K., Ohuchi E., Okada Y., and Hayakawa T. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta 221 (1993) 91-103
23. Fujimoto N., Hosokawa N., Iwata K., Shinya T., Okada Y., and Hayakawa T. A one-step sandwich enzyme immunoassay for inactive precursor and complexed forms of human matrix metalloproteinase 9 (92 kDa gelatinase/type IV collagenase, gelatinase B) using monoclonal antibodies. Clin Chim Acta 231 (1994) 79-88
24. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 30 (2007) S4-S41
25. Winer B.J. Statistical principles in experimental design. 2nd ed. (1971), McGraw-Hill, New York
26. Matthews J.N.S., Altman D.G., Campbell M.J., and Royton P. Analysis of serial measurements in medical research. BMJ 300 (1990) 230-235
27. Erdmann E., Dormandy J.A., Charbonnel B., Massi-Benedetti M., Moules I.K., Skene A.M., et al. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) study. J Am Coll Cardiol 49 (2007) 1772-1780
28. Hanefeld M., and Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 6 (2008) 153-163
29. Derosa G., Cicero A.F.G., Gaddi A., Ragonesi P.D., Fogari E., Bertone G., et al. Metabolic effects of Pioglitazone and Rosiglitazone in patients with diabetes and metabolic syndrome treated with Glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 26 (2004) 744-754
30. Asadollahi K., Beeching N., and Gill G. Hyperglycaemia and mortality. J R Soc Med 100 (2007) 503-507
31. Bell D.S., O'Keefe J.H., and Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?. Endocr Pract 14 (2008) 112-124
32. Petersen J.L., and McGuire D.K. Impaired glucose tolerance and impaired fasting glucose-a review of diagnosis, clinical implications and management. Diab Vasc Dis Res 2 (2005) 9-15
33. Hroussalas G., Kassi E., Dalamaga M., Delimaris I., Zachari A., and Dionyssiou-Asteriou A. Leptin, soluble leptin receptor, adiponectin and resistin in relation to OGTT in overweight/obese postmenopausal women. Maturitas 59 (2008) 339-349
34. Yamauchi J., Osawa H., Takasuka T., Ochi M., Murakami A., Nishida W., et al. Serum resistin is reduced by glucose and meal loading in healthy human subjects. Metabol 57 (2008) 149-156